Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Gundimeda, U., et al. 1996. J. Biol. Chem.271, 13504. Ye, Q. and Bodell, W.J. 1996. Carcinogenesis17, 1747. Laser, R., et al. 1985. Eur. J. Cancer Clin. Oncol.21, 985. Jordan, V.C., et al. 1978. J. Toxicol. Environ. Health4, 364.
Product Information
CAS number
68047-06-3
Form
Liquid
Formulation
A 10 mM (2 mg/516 µL) sterile-filtered solution of (Z)-4-Hydroxytamoxifen (Cat. No. 579002) in EtOH.
Keep away from sources of ignition - No Smoking. Keep container tightly closed.
Product Usage Statements
Storage and Shipping Information
Ship Code
Dry Ice Only
Toxicity
Harmful & Carcinogenic / Teratogenic
Hazardous Materials Attention:
Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
Storage
≤ -70°C
Protect from Light
Protect from light
Hygroscopic
Hygroscopic
Avoid freeze/thaw
Avoid freeze/thaw
Do not freeze
Ok to freeze
Special Instructions
Following initial thaw, aliquot and freeze (-20°C). Aliquots are stable for up to 6 months at -20°C. Use only anhydrous, 200 proof ethanol for further dilutions.
Packaging Information
Packaged under inert gas
Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
产品目录编号
GTIN
5.08225.0001
04055977261769
Documentation
InSolution™ Tamoxifen, 4-Hydroxy-, (Z)- - CAS 68047-06-3 - Calbiochem MSDS
Gundimeda, U., et al. 1996. J. Biol. Chem.271, 13504. Ye, Q. and Bodell, W.J. 1996. Carcinogenesis17, 1747. Laser, R., et al. 1985. Eur. J. Cancer Clin. Oncol.21, 985. Jordan, V.C., et al. 1978. J. Toxicol. Environ. Health4, 364.
数据表
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
A cell-permeable, active metabolite of Tamoxifen (Cat. No. 579000) that acts as a potent inhibitor of PKC. It is more potent than the parent compound and inhibits PKC by modifying its catalytic domain.
Form
Liquid
Formulation
A 10 mM (2 mg/516 µL) sterile-filtered solution of (Z)-4-Hydroxytamoxifen (Cat. No. 579002) in EtOH.
Intert gas (Yes/No)
Packaged under inert gas
CAS number
68047-06-3
Chemical formula
C₂₆H₂₉NO₂
Structure formula
Purity
≥99% by HPLC
Storage
Protect from light
Avoid freeze/thaw
≤ -70°C
Hygroscopic
Do Not Freeze
Ok to freeze
Special Instructions
Following initial thaw, aliquot and freeze (-20°C). Aliquots are stable for up to 6 months at -20°C. Use only anhydrous, 200 proof ethanol for further dilutions.
Toxicity
Harmful & Carcinogenic / Teratogenic
References
Gundimeda, U., et al. 1996. J. Biol. Chem.271, 13504. Ye, Q. and Bodell, W.J. 1996. Carcinogenesis17, 1747. Laser, R., et al. 1985. Eur. J. Cancer Clin. Oncol.21, 985. Jordan, V.C., et al. 1978. J. Toxicol. Environ. Health4, 364.